Hosted on MSN

AI and digital therapy show promise in education and health

Recent studies reveal that brief AI-led pre-lecture chats can match human instructors in enhancing learning, while a digital therapy app outperforms campus clinic referrals in improving student mental ...
Insider Monkey

Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever

Cingulate Inc. (NASDAQ:CING) is one of the best NASDAQ growth stocks to buy and hold forever. On March 18, Cingulate reported its financial results for Q4 and the full year 2025, highlighting the ...
Investing

Cingulate appoints new CCO, secures $6 million financing

Cingulate also completed a $6 million financing transaction with an accredited investor, structured as a non-convertible, unsecured promissory note accruing 9% annual interest and maturing in 18 ...
Nasdaq

Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control

Once-daily formulation of dexmethylphenidate achieved primary endpoint (p 0.001) with consistent symptom relief up to 12 hours post-dose KANSAS CITY, Kan., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cingulate ...
Investing

Cingulate secures manufacturing deal with Bend Bio Sciences for ADHD drug

KANSAS CITY - Cingulate Inc. (NASDAQ:CING), a clinical-stage biopharmaceutical company with a current market capitalization of $22 million, has entered into a commercial supply agreement with Bend Bio ...
The Business Journals

Cingulate puts CEO on leave days after second domestic battery arrest

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Cingulate Inc. placed its CEO on ...
Yahoo Finance

Cingulate Provides Management Team Update

KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CING) The Board of Directors of Cingulate Inc. (“Cingulate”) announced that it has placed Chairman and Chief Executive Officer, Shane J.
Nasdaq

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
PNAS

Decide, act, reflect, and maybe a self in all this?

Unlike the term “Default Mode Network” (DMN), which implied a functional role, “CON” was a purely anatomical label without carrying any functional meaning. It included regions with seemingly unrelated ...
Yahoo Finance

Cingulate Inc Secures $5M Financing for Strategic Growth

Cingulate Inc. has secured a $5 million financing arrangement through an unsecured promissory note with Streeterville Capital, LLC. The funds will support clinical, manufacturing, and regulatory ...
Benzinga.com

What's Going On With Cingulate Shares Recently?

Cingulate Inc. shares surged 30.7% amid strong investor interest in its ADHD treatment technology. Trading volume was high, with 3.297 million shares traded, reflecting growing market attention. Don’t ...